会议速递：抢先知！AACR2023肺癌最新研究

AEGEAN：新辅助度伐利尤单抗+化疗、度伐利尤单抗辅助治疗用于可切除NSCLC患者的III期试验

AEGEAN:A phase 3 trial of neoadjuvant durvalumab+chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC

报告人：John V.Heymach

摘要号：CT005

Tremelimumab+度伐利尤单抗+化疗一线治疗转移性NSCLC：POSEIDON研究中按bTMB分层的结果

Tremelimumab（T）+durvalumab（D）+chemotherapy（CT）in 1L metastatic NSCLC：Outcomes by blood tumor mutational burden（bTMB）in POSEIDON

报告人：Solange Peters

摘要号：CT080

新辅助纳武利尤单抗+化疗对比化疗用于可切除NSCLC中国患者：CheckMate 816

Neoadjuvant nivolumab（NIVO）+chemotherapy（chemo）vs chemo in Chinese patients（pts）with resectable NSCLC in CheckMate 816

报告人：天津医科大学肿瘤医院  王长利教授

摘要号：CT081

一项ctDNA指导的非小细胞肺癌患者分子反应适应性免疫化学治疗的多中心II期研究：CCTG BR.36第1阶段分析

A ctDNA-directed,multi-center phase II study of molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer:Analysis of Stage 1 of CCTG BR.36

报告人：Valsamo K.Anagnostou,

摘要号：CT212

Tusamitamab ravtansine（SAR408701）用于晚期非小细胞肺癌患者中的I/II期研究的生物标志物分析

Biomarker analysis from Phase 1/2 study of tusamitamab ravtansine（SAR408701）in patients with advanced non-small cell lung cancer（NSCLC）

报告人：Anas Gazzah

摘要号：CT213

Telisotuzumab vedotin(Teliso-V)二线/三线治疗MET基因扩增（MET Amp）、c-Met蛋白过表达（c-Met OE）的非鳞状非小细胞肺癌（NSQ NSCLC）的初步疗效：LUMINOSITY研究回顾性分析

Preliminary efficacy of telisotuzumab vedotin（Teliso-V）treatment in the 2L/3L setting in MET gene amplified（MET Amp），c-Met protein overexpressing（c-Met OE），non-squamous,non-small cell lung cancer（NSQ NSCLC）：Retrospective analysis of LUMINOSITY

报告人：D.Ross Camidge

摘要号：CT214

II期LCMC3研究中阿替利珠单抗辅助治疗的疗效和安全性

Efficacy and safety of adjuvant（adj）atezolizumab（atezo）from the Phase 2 LCMC3 study

报告人：David Paul Carbone

摘要号：CT215

不同血液肿瘤突变负荷（bTMB）非小细胞肺癌对帕博利珠单抗+化疗一线治疗的反应：II期KEYNOTE-782试验

Response to first-line（1L）pembrolizumab（pembro）+chemotherapy（chemo）in non-small cell lung cancer（NSCLC）by blood tumor mutational burden（bTMB）：the phase 2 KEYNOTE-782 trial

报告人：Jair Bar

摘要号：CT216

可切除的非小细胞肺癌患者阿替利珠单抗+化疗新辅助治疗的3年随访结果更新

3-year update of neoadjuvant atezolizumab+chemotherapy in patients with resectable non-small cell lung cancer

报告人：Brian S.Henick

摘要号：CT217

索凡替尼联合特瑞普利单抗一线治疗PD-L1表达阳性晚期非小细胞肺癌：一项多中心、单臂、II期研究

Surufatinib plus toripalimab for first-line treatment of advanced non-small cell lung cancer（NSCLC）with PD-L1 positive expression：A multicenter，single-arm phase 2 study

报告人：吉林省肿瘤医院程颖教授

摘要号：CT225

FHND9041胶囊作为EGFR敏感突变患者的一线治疗或T790M+晚期非小细胞肺癌患者的二/三线治疗的安全性、有效性和耐受性：I/II期单臂、多中心、开放标签研究的结果

Safety,efficacy,and tolerability of FHND9041 capsules as first-line treatment in patients with EGFR sensitive mutations or second/third-line treatment in patients with T790M+advanced non-small cell lung cancer（NSCLC）: results from a phase I/II single-arm, multi-center,open-label study

报告人：Yongqiang Zhu

摘要号：CT232

尼拉帕利+dostarlimab治疗复发的小细胞肺癌和其他高等级神经内分泌癌的II期试验

A phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas

报告人：Carl M.Gay

摘要号：CT218

低剂量放疗（LDRT）同步阿替利珠单抗（Atezo）加化疗作为ES-SCLC一线治疗的疗效和安全性：II期MATCH研究的初步分析

Efficacy and safety of Low dose radiotherapy（LDRT）concurrent Atezolizumab（Atezo）plus chemotherapy as first line（1L）therapy for ES-SCLC: Primary analysis of Phase II MATCH study

报告人：四川大学华西医院  周麟教授

摘要号：CT219

Rucaparib联合纳武利尤单抗前线维持治疗ES-SCLC的II期研究

Phase II of frontline maintenance rucaparib in combination with nivolumab in ES SCLC

摘要号：CT221